Clinical Trials
At MannKind, our commitment to clinical trials underscores our unwavering dedication to the well-being and safety of patients, along with our unrelenting pursuit of medical innovation. By dedicating substantial time, resources, and expertise to the meticulous execution of rigorous clinical trials, we firmly uphold the highest standards of scientific integrity.
Purpose
Clinical trials lie at the heart of MannKind’s pursuit to transform medical potential into tangible progress. Each trial illuminates the path toward more effective treatments and therapies. Through meticulous testing and observation, focused on ensuring safety, we uncover the insights that shape medical breakthroughs. At MannKind, our commitment to clinical trials echoes our commitment to humanity, as we work tirelessly to elevate healthcare standards and pave the way for a safer, healthier, and more equitable future.
Diversity
At MannKind, our unwavering commitment to safety and diversity in clinical trials is rooted in both science and compassion. We understand that behind every data point lies a person with a unique story, a journey, and a hope for better health. By intentionally embracing individuals from various backgrounds, ethnicities, ages, and genders in our participant pool, we aim to ensure that our research resonates the full gamut of individuals who will benefit from our medical products, all while prioritizing their safety. It’s a pursuit grounded not only in scientific integrity but also in empathy. By welcoming voices from all corners of society, we aim to foster a more inclusive and equitable future, where medical progress leaves no one behind. Through our collective efforts, we aspire to make a genuine difference in the lives of people everywhere.
ICoN-1 is a multi-national Phase 3, randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of Clofazimine Inhalation Suspension when added to Guideline-Based Therapy in adults with nontuberculous mycobacterial (NTM) lung disease followed by an open-label extension.
learn more
INHALE-1 is a Phase 3, randomized controlled trial in children and teenagers aged 4-17 with type 1 or type 2 diabetes to evaluate the efficacy and safety of inhaled insulin in combination with basal insulin versus multiple daily injections of rapid acting insulin in combination with basal insulin.
learn more
INHALE-3 is a Phase 4, randomized controlled trial to evaluate the efficacy and safety of inhaled insulin in combination with basal insulin versus usual care in adults with type 1 diabetes. Participants continue with their usual care or adopt an insulin regimen of inhaled insulin in combination with basal insulin, both groups utilizing continuous glucose monitoring (CGM).
learn moreEndocrine Scientific Advisory Board
TB
Thomas C. Blevins, MD, ECNU, FACE, FNLA
-Endocrinologist at Texas Diabetes and Endocrinology (Austin)
BB
Bruce W. Bode, MD, FACE
-Diabetes specialist, president and CEO of Atlanta Diabetes Associates (Atlanta)
-Clinical Associate Professor in the Department of Medicine at Emory University
AC
Anders L Carlson, MD
-Investigator for the International Diabetes Center at Park Nicollet (Minneapolis)
-Associate Professor at the University of Minnesota Medical School
KC
Kristin Castorino, D.O., BC-ADM
-Vice President, Clinical Research and Senior Investigator at Sansum Diabetes Research Institute (Santa Barbara, CA)
-Attending Physician at Santa Barbara County Health Care Center
EC
Eda Cengiz, MD, MHS
-Professor of Pediatrics at the University of California San Francisco School of Medicine (San Francisco)
-Benioff UCSF Professor in Children’s Health
-Director of the UCSF Pediatric Diabetes Program
GG
George Grunberger, MD, FACP, FACE
-Chairman of Grunberger Diabetes & Endocrinology (Bloomfield Hills, MI)
-Founder and Chief Medical Officer of HFWL COMPANY
-Clinical Professor of Internal Medicine and of Molecular Medicine & Genetics at Wayne State University School of Medicine
-Professor of Internal Medicine at Oakland University William Beaumont School of Medicine
-Visiting Professor at First Faculty of Medicine at Charles University in Prague (Czech Republic)
MH
Michael Haller, MD, MS-CI
-Professor and Chief of Pediatric Endocrinology at the University of Florida (Gainesville, FL)
KH
Korey Hood, PhD
-Professor & Behavioral Scientist at Stanford University
-Founder of DiabetesWise
DK
Davida Kruger, MSN, APN-BC, BC-ADM
-Certified nurse practitioner at Henry Ford Health System (Detroit)
-Division of Endocrinology, Diabetes, Bone and mineral disease
-Director of Clinical Research
-Supervisor Advanced Practice Providers
KL
Kashif Latif, MD
-Medical Director and Principal Investigator for AM Diabetes and Endocrinology Center (Bartlett, TN)
JM
Janet B. McGill, MD, MA, FACE, FACP
-Professor of Medicine in the Division of Endocrinology, Metabolism and Lipid Research at Washington University School of Medicine (St. Louis)
-Attending Physical at Barnes-Jewish Hospital
GS
Gary Scheiner, MS, CDCES
-Owner and Clinical Director of Integrated Diabetes Services (Wynnewood, PA)
AV
Amy M. Valent, D.O., M.C.R.
-Associate Professor in the Division of Maternal-Fetal Medicine, Department of Obstetrics & Gynecology at Oregon Health & Science University
-Medical Director, OHSU Diabetes and Pregnancy Program
PRODUCTS & PIPELINE
Check out our research and development pipeline focused on endocrine and orphan lung diseases.
explore our products & pipelinePUBLICATIONS
See how our technologies and therapies can help more people take control of their health.
view publications